03/17/2017

Updates to the NCCN Templates® have been made for Non-Small Cell Lung Cancer.

The following updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) have been made to reflect the NCCN Guidelines for Non-Small Cell Lung Cancer, Version 5.2017.

• The indication for template NSC61 – Ceritinib has been changed to “Advanced, Recurrent, or Metastatic: ALK rearrangement positive” (previously was “Advanced, Recurrent, or Metastatic: ALK rearrangement positive carcinoma intolerant to or progression on crizotinib”)
  • A new reference was also added: Soria JC, et al. Lancet. 2017;389(10072):917-929.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium, the NCCN Biomarkers Compendium^®, the NCCN Templates^®, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.